<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300768</url>
  </required_header>
  <id_info>
    <org_study_id>OCRC-33 - 980819(B)</org_study_id>
    <nct_id>NCT00300768</nct_id>
  </id_info>
  <brief_title>Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection</brief_title>
  <official_title>A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines Development for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines Development for Global Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and tolerability of moxidectin&#xD;
      in subjects infected with O. volvulus with special emphasis on Mazzotti reactions to&#xD;
      determine whether it is safe enough to expose a number of subjects sufficient for obtaining&#xD;
      statistically significant data on the safety and efficacy of moxidectin relative to&#xD;
      ivermectin.&#xD;
&#xD;
      Secondary objects are to determine the pharmacokinetics of moxidectin, to obtain initial&#xD;
      indication of the efficacy in terms of long term effect on skin microfilaria levels and an&#xD;
      indication of the effect on the macrofilaria that may underlie the effect on skin&#xD;
      microfilaria levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical adverse events and clinically significant laboratory test results</measure>
    <time_frame>Duration of follow up (18 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin mf counts at day 8 and months 1, 2, 3, 6, 12 and 18</measure>
    <time_frame>day 8 and months 1, 2, 3, 6, 12, 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nodulectomy at 18 months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PKs) at days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12</measure>
    <time_frame>days 1, 2, 4, 13, and 18 and months 1, 2, 3, 6 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>2 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg moxidectin (Dose-escalation 1st step)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin 150 mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator arm (ivermectin 150 mcg/kg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg moxidectin (dose escalation second step)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg moxidectin (dose escalation third step)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 mg moxidectin</intervention_name>
    <description>Single-dose, tablet encapsulated for blinding</description>
    <arm_group_label>2 mg moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin 150 mcg/kg</intervention_name>
    <description>Single-dose, tablets encapsulated for blinding</description>
    <arm_group_label>Ivermectin 150 mcg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg moxidectin</intervention_name>
    <description>Single dose, tablets encapsulated for blinding</description>
    <arm_group_label>4 mg moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8 mg moxidectin</intervention_name>
    <description>single dose, tablets encapsulated for blinding</description>
    <arm_group_label>8 mg moxidectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written, signed (or thumb-printed), and dated informed consent&#xD;
&#xD;
          2. Aged 18 to 60 years, inclusive&#xD;
&#xD;
          3. Body weight ≥ 40 kg for women and ≥ 45 kg for men&#xD;
&#xD;
          4. Nonpregnant, nonbreastfeeding women. Women of child bearing potential must agree to&#xD;
             use birth control during the first 150 days after treatment.&#xD;
&#xD;
          5. Healthy, as determined by a physician on the basis of a physical examination, ECG, and&#xD;
             a thorough review of the medical history and clinical laboratory results&#xD;
&#xD;
          6. Adequate hematologic, renal, and hepatic function&#xD;
&#xD;
          7. Skin microfilarial density within the required range for the cohort&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in any studies other than purely observational ones, within 4 weeks&#xD;
             before test article administration.&#xD;
&#xD;
          2. Any vaccination within 4 weeks before test article administration&#xD;
&#xD;
          3. Acute infection requiring therapy within the last 10 days before test article&#xD;
             administration&#xD;
&#xD;
          4. Administration of any medication (with the exception of medication required to treat&#xD;
             any reactions during the screening fluorescein angiography (chlorpheniramine) or&#xD;
             paracetamol) or herbal preparation within 10 days prior to test article administration&#xD;
             or any condition currently requiring regular medication&#xD;
&#xD;
          5. Clinically significant ECG abnormalities or history of cardiac abnormality&#xD;
&#xD;
          6. Past or current history of neurological or neuropsychiatric disease or epilepsy&#xD;
&#xD;
          7. Subjects with orthostatic hypotension at the screening evaluation&#xD;
&#xD;
          8. History of drug or alcohol abuse or regular use of ≥ 3 cigarettes per day&#xD;
&#xD;
          9. Use of alcohol or other drugs of abuse within 72 hours before test article&#xD;
             administration&#xD;
&#xD;
         10. Any condition, in the investigator's opinion, that places the subject at undue risk&#xD;
&#xD;
         11. Subjects who have donated blood within 8 weeks before study entry&#xD;
&#xD;
         12. Subjects with ocular onchocerciasis in cohorts intended to enroll subjects with mild&#xD;
             infection. Ocular onchocerciasis is defined by the presence of live or dead&#xD;
             microfilariae, onchocercal punctate opacities, onchocercal lesions of the posterior&#xD;
             segment or lesions that mimic those seen in onchocerciasis.&#xD;
&#xD;
         13. Subjects with hyperreactive onchodermatitis&#xD;
&#xD;
         14. Antifilarial therapy within the previous 5 years&#xD;
&#xD;
         15. Coincidental infection with Loa Loa&#xD;
&#xD;
         16. Female subjects of childbearing potential with a contraindication to DMPA if not on&#xD;
             Norplant&#xD;
&#xD;
         17. Any other condition which the investigator feels would exclude the subject from the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Opoku, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onchocerciasis Chemotherapy Research Center, Hohoe, Ghana</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onchocerciasis Chemotherapy Research Center</name>
      <address>
        <city>Hohoe</city>
        <state>Volta Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072596/pdf/pntd.0002953.pdf</url>
    <description>Awadzi et al 2014</description>
  </link>
  <results_reference>
    <citation>Awadzi K, Opoku NO, Attah SK, Lazdins-Helds J, Kuesel AC. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection. PLoS Negl Trop Dis. 2014 Jun 26;8(6):e2953. doi: 10.1371/journal.pntd.0002953. eCollection 2014 Jun.</citation>
    <PMID>24968000</PMID>
  </results_reference>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>March 7, 2006</study_first_submitted>
  <study_first_submitted_qc>March 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2006</study_first_posted>
  <last_update_submitted>November 15, 2017</last_update_submitted>
  <last_update_submitted_qc>November 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>onchocerciasis</keyword>
  <keyword>onchocerca volvulus</keyword>
  <keyword>river blindness</keyword>
  <keyword>ivermectin</keyword>
  <keyword>moxidectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
    <mesh_term>Intestinal Volvulus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Moxidectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

